Pre-made Tralokinumab biosimilar ( Whole mAb, anti-IL13 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-592
Anti-IL13 therapeutic antibody (Pre-made Tralokinumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and other inflammatory diseases. Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354 and taken through pre-clinical and early clinical development. After 2007 it has been developed by MedImmune, a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2b testing for atopic dermatitis. This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca's late stage development pipeline.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL13 therapeutic antibody (Pre-made Tralokinumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||5l6y:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune|
|Conditions Active||Atopic dermatitis;Alopecia areata|
|Conditions Discontinued||Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis|